10 results about "Neural tissues" patented technology

Techniques for measuring single synaptic signals under varying experimental conditions include controlling a video recording microscope to capture, at multiple different times, a first imaged area in a sample holder as a video frame when the sample holder is disposed on a stage and holds a sample of neuronal tissue combined with at least one fluorophore that emits a corresponding electromagnetic wavelength in a synapse during synaptic activity. At least one synaptic region of interest is determined based on a group of pixels in the first imaged area that record electromagnetic emissions from the fluorophore at the different times. An ordered time series of emission intensity is recorded in each of the synaptic region of interest. Peak emission intensity values in the time series are corrected for transmitter label transients. The ordered time series with corrected peak emission intensity values are stored in a data structure with a standard format.

A microelectrode probe for implantation in soft tissue, comprising a sheath of flexible polymeric material divided by a wall into a distal and a proximal compartment, said distal and proximal compartments being filled with a matrix of biocompatible material dissolvable or degradable in aqueous body fluids, and comprising a centrally disposed electrically conductive core passing through the wall and attached to it. The core is insulated at its proximal portion, from which it extends to a holder for attachment to tissue other than said soft tissue. The sheath and the core extending distally from said holder are embedded in a kindred additional matrix. The invention also discloses a method for its manufacture, an array comprising two or more microelectrode probes and a microelectrode probe for incorporation into the array and a method for the manufacture of the array.

In some embodiments, a method of providing a neurostimulation therapy to a patient comprises: generating, by an implantable pulse generator (IPG), electrical pulses comprising a plurality of pulses having a uniform pulse width over time and a pulse amplitude that changes over time, and applying the generated electrical pulses to neural tissue of the patient to inhibit neural activity of the patient. The pulse amplitude may change sinusoidally, linearly, or exponentially over time.

The present application proposes a system for differential recording in real-time navigation, connectable to an electrical lead having at least two electrodes, comprising: at least one electrical lead having a longitudinal axis and a distal end and at least two electrodes for recording electrical signals; a memory configured for storing a differential signal between the at least two electrodes and a reference indication of electrical signals associated with a neural tissue; a processing circuit, wherein the processing circuit: during advancement of the at least one electrical lead, computes in real-time a differential signal between electrical signals recorded from the at least two electrodes, processes the differential signal and the reference indication of electrical signals associated with the neural tissue; and computes an anatomical position of the electrical lead based on the processing, wherein the computing an anatomical position comprises estimating a proximity between at least one of the electrodes or the distal end of the electrical lead and a boundary between anatomical regions.

Automated assessment of neural response recordings involves storing a set of basis functions comprising at least one compound action potential basis function and at least one artefact basis function. Neural recordings of electrical activity in neural tissue are obtained by application of stimuli, using a single configuration of stimulation and recording. Each neural recording is decomposed by determining at least one parameter which estimates at least one of a compound action potential and an artefact. The at least one parameter is / are determined for each respective one of the plurality of neural recordings, to yield a plurality of values. A spread of the plurality of values is determined. An indication that the neural response recordings are of higher quality is output if the spread is small. An indication that the neural response recordings are of lower quality is output if the spread is large.

In one aspect, the disclosure relates to clearing compounds capable of rendering at least one tissue transparent for a period of time, compositions comprising the same, pendant molecules bonded to the compounds capable of covalently or non-covalently binding to tissue such as collagen mimetic peptide, and macromolecules derivatized with the same. In another aspect, the compositions can be useful in clinic for visualizing internal anatomical structures and / or for clearing opacities of the eye. In one aspect, the compositions are topical, e.g., eye drops, lotions, or creams, or are injectable. In some aspects, an injection is performed directly into opaque tissue such as neural tissue, connective tissue, internal organs, ocular tissue, or the like. In other aspects, the clearing compound is injected adjacent to the target structure. The clearing compounds can be colorless across the entire visible spectrum, are non-toxic, and are excreted by the subject after visualization of tissue structures.

There is provided a method and implantable device for controlling a neural stimulus, the neural stimulus being defined by an artefact mitigation status. The method comprises generating a first neural stimulus for delivery to neural tissue, sensing a first signal subsequent to the first neural stimulus, generating a second neural stimulus for delivery to the neural tissue, and sensing a second signal subsequent to the second neural stimulus. The method further comprises determining an artefact mitigation measure (AMM) effect level based on the first sensed signal and the second sensed signal, and setting, in response to comparing the AMM effect level with an AMM effect threshold, the artefact mitigation status of a third neural stimulus to active.

This invention provides a reduced single-atom nanomedicine, its preparation method, and its application, belonging to the field of nanobiomedicine technology. The single-atom nanomedicine prepared by this invention is a cerium single-atom-anchored phosphomolybdic acid nanocluster, namely Ce-POM. The preparation method includes using activated carbon as a substrate, adding a phosphomolybdic acid solution for loading, subsequently introducing cerium(III) acetylacetone hydrate for mixing and stirring, and finally calcining and reducing with hydrogen in a tubular furnace to obtain the Ce-POM single-atom nanomedicine. The Ce-POM nanomedicine of this invention possesses peroxidase-like and catalase-like activities. Through highly efficient multi-enzyme activity and charge migration, it promotes the consumption of reactive oxygen species (ROS), reduces cellular oxidative stress damage, inhibits ferroptosis, improves the microenvironment of neural tissue in cerebral hemorrhage, and promotes neural tissue repair. Simultaneously, the decrease in ROS levels further inhibits the activation of the intracellular immune signaling pathway cGAS-STING, regulates immune system function, protects neural cell repair, and achieves the ideal therapeutic effect for cerebral hemorrhage.

Disclosed are means of inducing and accelerating neurological recovery subsequent to a stroke through administration of amniotic fluid derived stem cells. In one embodiment stem cells are isolated from amniotic fluid and expanded under conditions allowing for expression of SSEA3, SSEA4, Tra1-60, Tra1-81, Tra2-54, Oct-4 and CD105. Said cells are subsequently administered into a patient having undergone a stroke, so as to induce direct regeneration (through transdifferentiation and replacement of neural tissue), as well as indirect regeneration (through production of growth factors that augment endogenous regenerative mechanisms while inhibiting degenerative mechanisms). In some embodiments factors produced by said amniotic fluid stem cells may be utilized instead of cells themselves. Said factors may include proteins, peptides, conditioned media, exosomes, or microvesicles.

This invention relates to the field of cell dedifferentiation, and more particularly to a method for promoting the dedifferentiation of satellite glial cells into neural stem cell-like cells. First, a three-dimensional composite hydrogel of nervonic acid-modified chitosan is constructed. Then, satellite glial cells are seeded and cultured in this hydrogel, inducing dedifferentiation to obtain a cell population with a neural stem cell-like phenotype. The hydrogel constructs a basic network through covalently linked amide bonds between nervonic acid and chitosan, and utilizes the hydrophobic association domains formed by the long-chain alkyl groups of nervonic acid to self-assemble into a covalently cross-linked + hydrophobically associated dual network structure. This simulates the softness, deformability, and local mechanical gradient properties of the neural tissue microenvironment, providing ideal dedifferentiation conditions for satellite glial cells to differentiate into neural stem cell-like cells. During the dedifferentiation process, markers such as Nestin, SOX2, and PAX6 are expressed, showing promising applications in neural regeneration, disease model construction, and cell therapy.